Latest Compugen News & Updates

See the latest news and media coverage for Compugen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Compugen

Clinical-stage biotech company discovering cancer immunotherapies

cgen.com

Headquarters: Holon, Israel
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Compugen

In short: Compugen achieved profitability and extended its cash runway to 2029 following major partnership deals and clinical pipeline advances.

Company announcements

May 18 Compugen

Compugen reported Q1 2026 financial results and pipeline progress

Cash runway extends into 2029; COM701 MAIA-ovarian trial actively enrolling; partners AstraZeneca and Gilead advancing programs.

March 2 Compugen

Compugen reports Q4 and full year 2025 results

Strengthened financial position via AstraZeneca deal and advanced clinical pipeline with COM701 and GS-0321.

18 December 2025 Compugen

Compugen monetizes portion of rilvegostomig royalties

The deal provides $65 million upfront plus $25 million milestone, preserves majority royalties, and is expected to extend cash runway into 2029.

10 November 2025 Compugen

Compugen reports third quarter 2025 financial results

The company posted a net loss of $6.98 million and provided clinical pipeline updates, with cash runway into Q3 2027.

Media coverage

July 14 Stockhouse

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types ...

June 26 The Globe and Mail

Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress

Compugen ( (CGEN)) has issued an update. Compugen on March 2, 2026, reported fourth-quarter and full-year 2025 results that showcased a dramatically strengthened balance sheet...

May 25 Investing.com

Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid...

Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges...

May 24 Ticker Report

Compugen Bets on COM701 Ovarian Cancer Trial as Gilead, AstraZeneca Deals Extend Runway - Ticker Report

Compugen (NASDAQ:CGEN) is focusing its near-term clinical strategy on a randomized ovarian cancer study of COM701 while continuing to rely on partnerships with Gilead Sciences...

Never miss news about Compugen

Track Compugen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Compugen competitors & trending companies

Browse news for competitors to Compugen and other trending companies.